SCHEMBL26038290

SCHEMBL26038290

Cc1c(-c2ccn(C(C)C)n2)sc2nc(-c3ccccn3)nc(N3CCC(CCO)C3)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.37
▸ METAP1 P53582 2/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ SYK P43405 4/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CFTR P13569 2/20 0.31
▸ KDM4E B2RXH2 3/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ SMO Q99835 1/20 0.30
▸ STAT3 P40763 1/20 0.30
▸ ADRB2 P07550 1/20 0.30
▸ ADRB1 P08588 1/20 0.30
▸ ADRB3 P13945 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24127737 0.90 PDE10A (0.35) HIF1ASYKNPSR1KDM4ESMN1; SMN2
SCHEMBL29720448 0.90 PDE10A (0.35) HIF1ASYKNPSR1KDM4ESMN1; SMN2
SCHEMBL26038293 0.89 POLB (0.38) HIF1AMETAP1SYKCFTRKDM4E
SCHEMBL26038980 0.89 HIF1A (0.33) HIF1AMETAP1NPSR1CFTRCYP1A2
SCHEMBL29720410 0.89 HIF1A (0.33) HIF1AMETAP1NPSR1CFTRKDM4E
SCHEMBL24127729 0.89 HIF1A (0.33) HIF1AMETAP1NPSR1CFTRKDM4E
SCHEMBL26038178 0.88 SYK (0.37) IRAK4SYK
SCHEMBL29720528 0.82 KDM4E (0.34) METAP1NPSR1CFTRKDM4EMAPT
SCHEMBL24128070 0.82 KDM4E (0.34) METAP1NPSR1CFTRKDM4EMAPT
SCHEMBL26038982 0.82 KDM4E (0.35) METAP1NPSR1CFTRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227466-A1 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227466-A1 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE KRAS, G3BP1, NRAS HIF1A 2256/4885METAP1 2626/4885IRAK4 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback